Disease relevance of Tongue Neoplasms

• MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer [1].
• Feeding of four phenolic compounds significantly reduced the incidences of tongue neoplasms (squamous cell papilloma and carcinoma) and preneoplastic lesions (hyperplasia and dysplasia) by 32 weeks, and rats fed CA or EA had no tongue neoplasms [2].
• Among 18 960 patients with non-Hodgkin's lymphoma (NHL), there was over a 3-fold significant increase in cancer of the tongue, small intestine, nose, kidney and nervous system, squamous cell carcinoma (SCC) of the skin, NHL, Hodgkin's disease (HD) and lymphoid and myeloid leukaemia [3].
• Oral glycopyrrolate alleviates drooling in a patient with tongue cancer [4].
• From this pilot study, it seems that PRLR negativity with hyperprolactinemia could be used as an independent predictor of short-term prognosis in cancer tongue patients [5].

Psychiatry related information on Tongue Neoplasms

• The demographic data and smoking and alcohol consumption history of the 7 NPC patients who subsequently developed tongue cancer were significantly different from the de novo tongue cancer patient population [6].

High impact information on Tongue Neoplasms

• Loss of Fhit expression is a predictor of poor outcome in tongue cancer [7].
• When fed the test compounds singly or the combination regimen after 4-NQO exposure, the frequency of tongue cancer was also decreased [diosmin, 77% reduction (P < 0.005); hesperidin, 62% reduction (P < 0.05); and the combination regimen, 77% (P < 0.005)] [8].
• Thirty-two weeks after the start of the study, the incidence of tongue neoplasms and preneoplastic lesions, polyamine levels in the tongue epithelium, and cell proliferation activity estimated by bromodeoxyuridine labeling index were compared among the different dietary groups [9].
• Chemoprevention of oral carcinogenesis by DL-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor: dose-dependent reduction in 4-nitroquinoline 1-oxide-induced tongue neoplasms in rats [10].
• Although the precise mechanism of the effect of bleomycin on nuclear activities of human tongue cancer cells remains unsettled because of the lack of cytochemical analysis, it is believed that bleomycin inhibits DNA synthesis and might also activate ribosomal RNA synthesis [11].

Chemical compound and disease context of Tongue Neoplasms

• An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies [12].
• Here, we provide molecular evidence associated with the anti-metastatic effect of silibinin by showing a marked inhibition of the invasion and motility of SCC-4 tongue cancer cells, with 89% and 66.4% of inhibition, respectively, by 100 muM of silibinin [13].
• Split course interstitial brachytherapy with a source shift: the results of a new iridium implant technique versus single course implants for salvage irradiation of base of tongue cancers in 55 patients [14].
• In this article we describe a patient with tongue cancer who was successfully treated with oral glycopyrrolate 0.4 mg 3 times daily [4].
• Acute reversible encephalopathy after repeated low-dose cisplatin infusions and concomitant radiotherapy for cancer of the tongue [15].

Biological context of Tongue Neoplasms

• Five quantitative trait loci affecting 4-nitroquinoline 1-oxide-induced tongue cancer in the rat [16].
• CDDP induces p53-dependent apoptosis in tongue cancer cells [17].
• The purpose of this investigation was to evaluate cell cycle proteins (p53, p21, Rb, MDM2) in lateral tongue cancers from patients at the two ends of the age spectrum [18].

Anatomical context of Tongue Neoplasms

• Differential expression of cytokeratin after orthotopic implantation of newly established human tongue cancer cell lines of defined metastatic ability [19].
• Multivariate analysis confirmed that in addition to pathological stage and regional lymph node status, cyclin D1 overexpression and loss of p16INK4A expression are independent predictors of death from tongue cancer [20].
• Lidocaine administered topically within the oral cavity for cancer pain relief may suppress the proliferation of human tongue cancer cells [21].
• New superselective intra-arterial infusion via superficial temporal artery for cancer of the tongue and tumour tissue platinum concentration after carboplatin (CBDCA) infusion [22].

Gene context of Tongue Neoplasms

• CONCLUSIONS: This multifaceted study of PRL suggests that tongue cancer cells produce PRL, and this ectopically produced PRL might be acting as a major local growth promoter by means of autocrine and paracrine mechanisms [23].
• Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression [24].
• Pre-therapeutic circulating prolactin levels and tumoral prolactin receptors (PRLR) were determined in 25 male patients with tongue cancer [5].
• We conclude that p53, p21, Rb, and MDM2 are over-expressed in lateral tongue cancers, and that immunohistochemical profiles are heterogeneous [18].
• Immunohistochemical detection of nuclear proteins cyclin D1, p53, and p16INK4A, and the Ki-67 labeling index was undertaken in tissue sections from 148 tongue cancers treated by surgical resection [20].

Analytical, diagnostic and therapeutic context of Tongue Neoplasms

• There was a significantly increased number of tongue cancers following radiotherapy for NPC [6].
• STUDY DESIGN: Retrospective study of 332 patients with oral tongue cancer treated in the Departments of Otolaryngology-Head and Neck Surgery and Radiation Therapy at Washington University School of Medicine (St. Louis, MO) from 1957 to 1996 [25].
• Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for tongue cancer [26].
• PURPOSE: This study investigated the in vivo antitumor effects of electrochemotherapy (ECT) using electroporation and bleomycin in a hamster tongue cancer model to assess its clinical applicability [27].

References